Trade RNAZ stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
TransCode Therapeutics, Inc. (RNAZ) is trading at US$1.74, down 6.45% today as of Oct 12, 14:36 EDT. The company has a market capitalisation of US$3.04M. Over the past 52 weeks, RNAZ has traded between US$1.52 and US$15.90. On Syfe you can trade RNAZ with $0 commission and add it to your watchlist.
| Previous close | US$1.86 |
|---|---|
| Market cap | US$3.04M |
| 52-week range | US$1.52 – US$15.90 |
| Volume | 84.08K |
| Exchange | US |
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. Its lead product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.
Year: 2021
TransCode Says Phase 1a Cancer Trial Meets Safety Goal, Advances Drug to Phase 2a
Jun 3, 1:04 PM · MT Newswires
TransCode Registers 1.53 Million Shares for YA II PN Resale Under Equity Purchase Deal
May 1, 2:43 PM · MT Newswires
TransCode Therapeutics, Inc. (RNAZ) stock is trading at US$1.74, -6.45% from the previous close of US$1.86.
The market cap for TransCode Therapeutics, Inc. (RNAZ) stock is approximately US$3.04M.
The 52-week high for TransCode Therapeutics, Inc. (RNAZ) stock is US$15.90.
The 52-week low for TransCode Therapeutics, Inc. (RNAZ) stock is US$1.52.
TransCode Therapeutics, Inc. (RNAZ) does not currently pay a dividend.
Stay on top of RNAZ
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
